This application represents the second competitive renewal of the CALGB institutional grant submission from the University of North Carolina at Chapel Hill (UNC-CH) and its affiliates. UNC-CH has been a member of CALGB since 1986. We have maintained an average annual accrual of 120 cases from 1992-1996 and with the addition of seven new affiliates, including the University of Alabama at Birmingham in the last three years, are projecting more than 150 in the coming years. Approximately 60 percent of our total accrual is from our affiliates. Our overall minority accrual of percent remains at two one-half times the group average. This has resulted in our obtaining a Minority Initiative Program Grant from the group for 1997 and an application from UNC for continued Minority Initiative Program funding during the coming Grant cycle. Our multidisciplinary efforts and significant contributions to surgical studies in the group has also resulted in our being one of 12 Group Institutions with funding from the Surgery Grant on which Dr. David Sugarbaker is the Principal Investigator. Moreover, our institution has demonstrated broad leadership participation in the group in Radiation Oncology, Leukemia, Lymphoma, Breast, Transplant, Correlative Sciences, Epidemiology, Pathology, Cancer Prevention and Control, and GI Cancer and is the research base for a Minority CCOP at our affiliate, the Medical College of Virginia. During the past funding cycle, we have had the distinction of having two committee chairs, four committee vice-chairs, one working group chair, 28 Core and Executive Committee members, 12 protocol principal investigators or co-investigators and two members of the Board of Directors. This has ranked UNC consistently among the top two or three institutions in the """"""""leadership"""""""" category of the internal CALGB Group scoring system. We plan to continue direct service to the group by maintaining an active reference laboratory in molecular epidemiology and an independently funded core facility for banking of germ line DNA for genetic studies in patients with breast cancer and other solid tumors. Although Dr. Edison Liu's departure to the NCI is a loss for UNC and the entire group, Ms. Lynn Dressler has extensive experience in performing correlative studies within the Cooperative Groups and will be more than able to continue the work which she and Dr. Liu had initiated. We believe that this application reflects the growing and crucial contribution that UNC-CH investigators provide to the group in leadership, science, and service as well as our commitment to increase accrual through the addition of major affiliates while maintaining rigorous quality control of data submission. We respectfully submit that this application demonstrates both the value of this institution to the group and the contributions that UNC-CH and its affiliates will provide in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA047559-08
Application #
2599516
Study Section
Subcommittee G - Education (NCI)
Program Officer
Kaplan, Richard S
Project Start
1991-06-01
Project End
2001-03-31
Budget Start
1998-06-03
Budget End
1999-03-31
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Morrison, Vicki A; McCall, Linda; Muss, Hyman B et al. (2018) The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol 9:228-234
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Giuliano, Armando E; Ballman, Karla V; McCall, Linda et al. (2017) Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318:918-926
Mandelblatt, Jeanne S; Cai, Ling; Luta, George et al. (2017) Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat 164:107-117
Freedman, Rachel A; Foster, Jared C; Seisler, Drew K et al. (2017) Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. J Clin Oncol 35:421-431
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050

Showing the most recent 10 out of 149 publications